TABLE 4.
Results of pairwise meta-analyses for the BI score.
| Comparative | Reference medications | Number of studies | Number of controls | Number of patients | MD/OR | 95% CI | I2 | p |
|---|---|---|---|---|---|---|---|---|
| Nimodipine | Placebo | 2 | 76 | 78 | 2.29 | [-17.45, 22.03] | 0 | 0.38 |
| Citicoline | Placebo | 1 | 60 | 60 | 3.36 | [2.80, 3.93] | 0 | 0.00001 |
| Oxiracetam | Placebo | 4 | 172 | 172 | 2.24 | [0.37, 4.11] | 0 | 0.032 |
| NBP | Placebo | 2 | 88 | 88 | 13.53 | [9.84, 17.22] | 0 | 0.014 |
| Donepezil | Placebo | 2 | 79 | 79 | 1.48 | [1.13, 1.83] | 0 | 0.0001 |
| Salvianolate | Placebo | 11 | 769 | 773 | 7.69 | [5.15, 10.21] | 0 | 0.00001 |
| TCM | Placebo | 5 | 200 | 200 | 12.36 | [8.79, 15.92] | NA | 0.07 |
| Olacetam | Placebo | 5 | 211 | 208 | 8.71 | [17.19, 20.24] | 0 | 0.01 |
CI, confidence interval; MD, mean difference; OR, risk ratio; I2, heterogeneity; TCM, traditional chinese medicine; NBP, DL-3-n-Butylphthalide.